NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
Clinical Trials
11 trialsNCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT02977689 2017-12-20
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT02987010 2017-10-11
Phase 2 Study of IDH305 in Low Grade Gliomas
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT01445691 2016-05-17
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT01249105 2016-03-10
MK-2206 for Recurrent Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01952886 2014-09-22
Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients
Duke University
Phase 2 Withdrawn
NCT01778088 2014-02-25
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
Cellectar Biosciences, Inc.
Phase 2 Withdrawn
NCT00797940 2012-12-03
CLARITY-1
Protox Inc.
Phase 2 Withdrawn
NCT00005083 2012-10-04
Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00243490 2010-01-12
Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors
National Taiwan University Hospital
Phase 2 Withdrawn